Biogen Aktie 1720684 / US09062X1037
146.59
USD
-0.78
USD
-0.53%
20.12.2024
BTT
| Kurse + Charts + Realtime | News + Analysen | Fundamental | Unternehmen | zugeh. Wertpapiere | Aktion | |
|---|---|---|---|---|---|---|
| Kurs + Chart | Chart (gross) | News + Adhoc | Bilanz/GuV | Termine | Strukturierte Produkte | Portfolio |
| Times + Sales | Chartvergleich | Analysen | Schätzungen | Profil | Watchlist | |
| Börsenplätze | Realtime Push | Kursziele | Dividende/GV | |||
| Orderbuch | Analysen | |||||
| Historisch | ||||||
Kurse + Charts + Realtime
News + Analysen
Fundamental
zugeh. Wertpapiere
Biogen Dividenden Kalender
| Datum | Name | Rendite * | Dividende | Währung |
|---|---|---|---|---|
| 2023 | Biogen Inc | 0.00 | 0.00 | USD |
| 2022 | Biogen Inc | 0.00 | 0.00 | USD |
| 2021 | Biogen Inc | 0.00 | 0.00 | USD |
| 2020 | Biogen Inc | 0.00 | 0.00 | USD |
| 2019 | Biogen Inc | 0.00 | 0.00 | USD |
| 2018 | Biogen Inc | 0.00 | 0.00 | USD |
| 2017 | Biogen Inc | 0.00 | 0.00 | USD |
| 2016 | Biogen Inc | 0.00 | 0.00 | USD |
| 2015 | Biogen Inc | 0.00 | 0.00 | USD |
| 2014 | Biogen Inc | 0.00 | 0.00 | USD |
Gewinn je Aktie- Biogen
| 8.0 23 | 20.9 22 | 10.4 21 | 24.8 20 | 31.4 19 | 21.6 18 | 11.9 17 |
Umsatz je Aktie- Biogen
| 64.7 23 | 64.6 22 | 69.5 21 | 76.6 20 | 67.8 19 | 58.7 18 | 51.6 17 |
KGV- Biogen
| 32.4 23 | 13.3 22 | 23.1 21 | 9.9 20 | 9.4 19 | 13.9 18 | 26.7 17 |
Biogen Inc: Die Aktie (in USD)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|
| Gewinn je Aktie berichtet | 7.97 | 20.87 | 10.40 | 24.80 | 31.42 | 21.58 | 11.92 |
| Gewinn je Aktie unverwässert | 8.02 | 20.97 | 10.44 | 24.86 | 31.47 | 21.62 | 11.94 |
| Gewinn je Aktie verwässert | 7.97 | 20.87 | 10.40 | 24.80 | 31.42 | 21.58 | 11.92 |
| Dividende pro Aktie | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gesamtdividendenausschüttung in Mio. | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Biogen Inc: Unternehmenskennzahlen (in USD)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|
| Umsatz je Aktie | 64.68 | 64.61 | 69.53 | 76.60 | 67.84 | 58.71 | 51.60 |
| KGV (Jahresendkurs, EPS unverwässert) | 32.45 | 13.27 | 23.07 | 9.87 | 9.44 | 13.94 | 26.73 |
| KGV (Jahresendkurs, EPS verwässert) | 32.45 | 13.27 | 23.07 | 9.87 | 9.44 | 13.94 | 26.73 |
| KGV (Jahresendkurs) | 32.45 | 13.27 | 23.07 | 9.87 | 9.44 | 13.94 | 26.73 |
| Dividendenrendite Jahresende in % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Eigenkapitalquote in % | 55.13 | 54.53 | 45.90 | 43.41 | 48.98 | 51.53 | 53.26 |
| Fremdkapitalquote in % | 44.87 | 45.47 | 54.10 | 56.59 | 51.02 | 48.47 | 46.74 |
Biogen Inc: GuV (in Mio. USD)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|
| Umsatzerlöse | 9’417.00 | 9’433.40 | 10’402.40 | 12’356.00 | 12’714.00 | 12’052.70 | 10’990.00 |
| Umsatzveränderung in % | -0.17 | -9.32 | -15.81 | -2.82 | 5.49 | 9.67 | 7.81 |
| Bruttoergebnis vom Umsatz | 6’388.80 | 6’636.40 | 7’805.40 | 10’093.80 | 10’294.00 | 9’855.20 | 8’576.50 |
| Bruttoergebnisveränderung in % | -3.73 | -14.98 | -22.67 | -1.94 | 4.45 | 14.91 | 2.25 |
| Operatives Ergebnis | 1’631.30 | 2’274.10 | 2’865.20 | 3’800.30 | 5’829.30 | 5’162.60 | 4’405.90 |
| Veränderung Operatives Ergebnis in % | -28.27 | -20.63 | -24.61 | -34.81 | 12.91 | 17.17 | -1.35 |
| Ergebnis vor Steuern | 1’296.80 | 3’591.80 | 1’745.20 | 5’047.50 | 7’125.90 | 5’899.60 | 5’128.80 |
| Veränderung Ergebnis vor Steuern in % | -63.90 | 105.81 | -65.42 | -29.17 | 20.79 | 15.03 | 3.97 |
| Ergebnis nach Steuer | 1’161.10 | 3’046.90 | 1’556.10 | 4’000.60 | 5’888.50 | 4’430.70 | 2’539.10 |
| Veränderung Ergebnis nach Steuer in % | -61.89 | 95.80 | -61.10 | -32.06 | 32.90 | 74.50 | -31.43 |
Biogen Inc: Bilanz (in Mio. USD)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|
| Gesamtverbindlichkeiten | 12’045 | 11’166 | 12’918 | 13’933 | 13’895 | 12’257 | 11’055 |
| Langzeit Gesamtverbindlichk. pro Aktie | 59.43 | 54.77 | 58.64 | 66.87 | 51.85 | 45.45 | 36.34 |
| Eigenkapital | 14’799 | 13’388 | 10’960 | 10’686 | 13’339 | 13’032 | 12’598 |
| Veränderung Eigenkapital in % | 10.46 | 22.96 | 1.83 | -19.81 | 2.33 | 3.38 | 3.89 |
| Bilanzsumme | 26’845 | 24’554 | 23’877 | 24’619 | 27’234 | 25’289 | 23’653 |
| Veränderung Bilanzsumme in % | 9.33 | 2.83 | -3.01 | -9.60 | 7.69 | 6.92 | 3.39 |
Biogen Inc: Sonstige Angaben (in USD)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|
| Gewinn je Aktie (unverwässert) | 8.02 | 20.97 | 10.44 | 24.86 | 31.47 | 21.62 | 11.94 |
| Veränderung Gewinn je Aktie (unverwässert) in % | -61.73 | 100.92 | -58.03 | -21.00 | 45.55 | 81.10 | -29.57 |
| Gewinn je Aktie (verwässert) | 7.97 | 20.87 | 10.40 | 24.80 | 31.42 | 21.58 | 11.92 |
| Veränderung Gewinn je Aktie (verwässert) in % | -61.79 | 100.63 | -58.06 | -21.07 | 45.61 | 81.04 | -29.56 |
| Anzahl Mitarbeiter | 7’570 | 8’725 | 9’610 | 9’100 | 7’400 | 7’800 | 7’300 |
| Veränderung Anzahl Mitarbeiter in % | -13.24 | -9.21 | 5.60 | 22.97 | -5.13 | 6.85 | -1.35 |
Biogen Inc Termine
| Unternehmen | Event | Datum |
|---|---|---|
| Biogen Inc | Quartalszahlen | 30.01.2025 |
| Biogen Inc | Quartalszahlen | 23.04.2025 |
| Biogen Inc | Quartalszahlen | 29.07.2025 |
| Biogen Inc | Quartalszahlen | 28.10.2025 |
Biogen Inc vergangene Termine
| Terminart | Info | Datum |
|---|---|---|
| Quartalszahlen | Q3 2024 Earnings Release | 30.10.2024 |
| Quartalszahlen | Q2 2024 Earnings Release | 01.08.2024 |
| Hauptversammlung | Annual General Meeting | 20.06.2024 |
| Quartalszahlen | Q1 2024 Earnings Release | 24.04.2024 |
| Quartalszahlen | Q4 2023 Earnings Release | 13.02.2024 |
| Quartalszahlen | Q3 2023 Earnings Release | 08.11.2023 |
| Quartalszahlen | Q2 2023 Earnings Release | 25.07.2023 |
| Hauptversammlung | Annual General Meeting | 26.06.2023 |
| Quartalszahlen | Q1 2023 Earnings Release | 25.04.2023 |
| Quartalszahlen | Q4 2022 Earnings Release | 15.02.2023 |
| Quartalszahlen | Q3 2022 Earnings Release | 25.10.2022 |
| Quartalszahlen | Q2 2022 Earnings Release | 20.07.2022 |
| Hauptversammlung | Annual General Meeting | 15.06.2022 |
| Quartalszahlen | Q1 2022 Earnings Release | 03.05.2022 |
| Quartalszahlen | Q4 2021 Earnings Release | 03.02.2022 |
Aktionärsstruktur
| Inhaber | in % |
|---|---|
| Freefloat | 99.29 |
| The Vanguard Group, Inc. | 11.45 |
| PRIMECAP Management Co. | 11.20 |
| PRIMECAP Management Co. | 11.16 |
| Vanguard Group, Inc. (Subfiler) | 11.00 |
| Vanguard PRIMECAP Fund | 6.30 |
| SSgA Funds Management, Inc. | 5.04 |
| State Street Corp. | 5.04 |
| BlackRock Fund Advisors | 3.53 |
| Wellington Management Co. LLP (Wellington Breakout) | 3.43 |
| Vanguard Total Stock Market ETF | 3.16 |
| Vanguard Health Care Fund | 3.13 |
| T. Rowe Price Investment Management, Inc. | 2.92 |
| Vanguard 500 Index Fund | 2.65 |
| Geode Capital Management LLC | 2.48 |
*Die Summe der Anteile kann 100% überschreiten, da bestimmte Anteilseigner zum Freefloat dazu gerechnet wurden.
Personal
| 2017 | 2018 | 2019 | 2020 | 2021 | |
|---|---|---|---|---|---|
| Personal am Ende des Jahres | 7’300 | 7’800 | 7’400 | 9’100 | 9’610 |
| Umsatz pro Mitarbeiter in Mio. EUR | 1.51 | 1.55 | 1.72 | 1.36 | 1.08 |
Bilanz (in Mio. USD) - Aktiva
| 2017 | 2018 | 2019 | 2020 | 2021 | |
|---|---|---|---|---|---|
| Summe Umlaufvermögen | 7’873 | 7’641 | 8’382 | 6’887 | 7’857 |
| Summe Anlagevermögen | 15’779 | 17’648 | 18’853 | 17’732 | 16’021 |
| Summe Aktiva | 23’653 | 25’289 | 27’234 | 24’619 | 23’877 |
Bilanz (in Mio. USD) - Passiva
| 2017 | 2018 | 2019 | 2020 | 2021 | |
|---|---|---|---|---|---|
| Summe Fremdkapital | 11’055 | 12’257 | 13’895 | 13’933 | 12’918 |
| Summe Eigenkapital | 12’598 | 13’032 | 13’339 | 10’686 | 10’960 |
| Summe Passiva | 23’653 | 25’289 | 27’234 | 24’619 | 23’877 |
Adresse
| 225 Binney Street, 02142 Cambridge | |
| Telefon | +1 (617) 679-2000 |
| URL | http://www.biogen.com |
Management
|
Adam Keeney
Executive VP & Head-Corporate Development |
|
Anabella Villalobos
SVP-Biotherapeutic & Medicinal Sciences |
|
Caroline D. Dorsa
Chairman |
|
Christopher A. Viehbacher
President, Chief Executive Officer & Director |
|
Daniel Quirk
Chief Medical Officer & Head-Medical Affairs |
|
Eric K. Rowinsky
Independent Director |
|
Ginger Gregory
Chief Human Resources Officer & Executive VP |
|
Jake Elkins
Vice President & Head-Acute Neurology Research |
|
Jane Grogan
Executive Vice President & Head-Research |
|
Jesus B. Mantas
Independent Director |
|
Lloyd B. Minor
Director |
|
Maria C. Freire
Independent Director |
|
Menelas NICOLAS Pangalos
Director |
|
Michael E. Dambach
Treasurer & Vice President |
|
Michael Hencke
Executive Director-Investor Relations |
|
Michael R. McDonnell
Chief Financial Officer & Executive Vice President |
|
Monish Patolawala
Independent Director |
|
Nancy A. Simonian
Vice President-Medical Research & Development |
|
Nicole Murphy
Head-Pharmaceutical Operations & Technology |
|
Priya Singhal
Head-Development |
|
Rachid Izzar
Executive Vice President |
|
Robert Kilo
Account Director |
|
Robin C. Kramer
Chief Accounting Officer & Senior Vice President |
|
Stephen A. Sherwin
Independent Director |
|
Susan H. Alexander
Chief Legal Officer & Executive Vice President |
|
Susan Langer
Independent Director |
|
Timothy Power
Head-Investor Relations |
|
Tom Holmes
Senior Director-External Manufacturing |
|
Wendell C. Taylor
Secretary & Chief Counsel |
|
William A. Hawkins
Independent Director |
|
Xu Cheryl
Vice President-Public Policy & Government Affairs |